More Videos
- Pfizer's Statin Study: What A Coincidence!
- Sam Waksal: "Moving On Up" To The East Side
- Another "Short" Story About Pfizer & Dendreon
- Predictions: 9 For '09 In Pharma
- Johnson & Johnson Is Latest FDA Casualty
- Genentech: Roche Says One Thing, Investors Say Another
- Schering-Plough: The Reviews Are In
- Pharma Updates And What You Need To Know
- The Emails Fly On GM, Ford CEO's Corporate Jets
- Merck Offering To Help Patients—Or Itself?
- Lightning Round: Microsoft, Motorola, NYSE and More
- Lightning Round OT: Hertz, Textron and More
- Mad Mail: Cramer's Plan for the SEC
- The Plaxico Burress Good Judgment Award
- Cramer's Call on Celgene
- Your First Move For Thursday December 4th
- Web Extra: Fast & Furious Trades For Thursday
- Cramer's M&A Plays
- Retailers Move Market?
- Nomura to Cut Up to 1,000 Positions in London
- Capital One to Purchase Chevy Chase
- Australia Economy Injured as Vehicle Sales Crash
- <Headline>Japan Faces Deep Recession, Central Banks Cut Rates</Headline>
- Banks Throw Babcock & Brown a Lifeline
- Japan Capex Data Signals Downward Revision in GDP
- Japan's Nippon Oil, Nippon Mining Plan to Merge
- <Headline>Asian Markets Are Mixed, Focus on Central Banks</Headline>
- Congress Briefed by US Auto Firms on Revamp Plans
Text Size 
 |
CNBC.com |
] is worth more than the former sector king. Elizabeth Trotta at TheStreet.com took note of this late last week but I thought it was worth pointing out. Gilead Sciences [GILD
Loading...
()
] has overtaken Amgen as the world's second most highly valued biotech. Genentech [DNA
Loading...
()
] is the commanding number one with a market cap of more than $83 billion. It's a little nip and tuck between GILD and AMGN, but as I write this Amgen's market cap stands at approximately $43.5 billion and Gilead's at $45.5 billion. Amgen is still tops when it comes to revenue: $14.8 billion in 2007 versus Genentech's $11.7 billion and Gilead's $4.2 billion.
There's a lot of analyst commentary rolling out regarding the potential impact of the pending court decision on Roche launching a competitor to Amgen's anemia drugs in the U.S. AMGN shares fell about 10 percent last week to a new multi-year low on that fear. But this morning Cowen and Co. biotech analyst Eric Schmidt writes in a research note to clients, "We expect Amgen shares to recover as investors gain conviction that Amgen will continue to benefit from its intellectual property on (the anemia drugs)."
related content |
But Rodman & Renshaw's Mike King in a note to clients this morning writes that there's more than the judge's ruling is weighing on the stock. "We expect continued share pressure and are maintaining our Market Perform rating at least until the FDA renders its final decision on the Aranesp restrictions (in cancer patients)....," King says. The agency is expected to issue its ruling in around 30-45 days or so. R&R and Cowen make a market in AMGN.
Finally, I wanted to provide a couple of links to an interview I did with "The Disciplined Investor" blogger Andrew Horowitz about all things pharma and biotech. We cover Merck to Dendreon.You can check it out on the web at or on iTunes.
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes